Tyrosine-protein kinase Fgr
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tyrosine-protein kinase Fgr as ChEMBL target CHEMBL4454, mapped to UniProt P09769. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Tyrosine-protein kinase Fgr matters
Tyrosine-protein kinase Fgr is reviewed as Tyrosine-protein kinase Fgr (UniProt P09769); the current evidence base includes 23 approved drugs, 1154 compounds, and 347 assays, with lead potency reaching pChEMBL 9.5.
Tyrosine-protein kinase Fgr Sequence length is 529 aa.
Review this target as Tyrosine-protein kinase Fgr, mapped to UniProt P09769. Sequence length is 529 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 23 approved drugs, 1154 compounds, and 347 assays for this target. The dominant activity type is KD. CHEMBL249097 is the current potency anchor at pChEMBL 9.5.
Use CHEMBL249097 as the tractability anchor when discussing potency (pChEMBL 9.5).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Tyrosine-protein kinase Fgr matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P09769, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL249097
|
9.5 | Kd | — |
|
|
No preferred name
CHEMBL3647967
|
9.4 | IC50 | — |
|
|
No preferred name
CHEMBL5416410
|
9.3 | Kd | Approved |
|
|
No preferred name
CHEMBL388978
|
9.2 | IC50 | — |
|
|
No preferred name
CHEMBL364623
|
9.1 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
ZANUBRUTINIB
CHEMBL3936761
|
2019 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
IBRUTINIB
CHEMBL1873475
|
2013 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
AXITINIB
CHEMBL1289926
|
2012 |
|
|
VANDETANIB
CHEMBL24828
|
2011 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
NILOTINIB
CHEMBL255863
|
2007 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
SUNITINIB
CHEMBL535
|
2006 |